Network of microRNAs-mRNAs Interactions in Pancreatic Cancer

Elnaz Naderi,1 Mehdi Mostafaei,2 Akram Pourshams,1 and Ashraf Mohamadkhani1

1 Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2 Biotechnology Engineering, Islamic Azad University, Tehran North Branch, Tehran, Iran

Correspondence should be addressed to Ashraf Mohamadkhani; mohamadkhani.ashraf@gmail.com

Received 5 February 2014; Revised 13 April 2014; Accepted 13 April 2014; Published 7 May 2014

Background. MicroRNAs are small RNA molecules that regulate the expression of certain genes through interaction with mRNA targets and are mainly involved in human cancer. This study was conducted to make the network of miRNAs-mRNAs interactions in pancreatic cancer as the fourth leading cause of cancer death.

Methods. 56 miRNAs that were exclusively expressed and 1176 genes that were downregulated or silenced in pancreas cancer were extracted from beforehand investigations. MiRNA–mRNA interactions data analysis and related networks were explored using MAGIA tool and Cytoscape 3 software. Functional annotations of candidate genes in pancreatic cancer were identified by DAVID annotation tool.

Results. This network is made of 217 nodes for mRNA, 15 nodes for miRNA, and 241 edges that show 241 regulations between 15 miRNAs and 217 target genes. The miR-24 was the most significantly powerful miRNA that regulated series of important genes. ACVR2B, GFRA1, and MTHFR were significant target genes that were downregulated.

Conclusion. Although the collected previous data seems to be a treasure trove, there was no study simultaneous to analysis of miRNAs and mRNAs interaction. Network of miRNA-mRNA interactions will help to corroborate experimental remarks and could be used to refine miRNA target predictions for developing new therapeutic approaches.

1. Introduction

Pancreatic cancer has introduced itself as one of the top five causes of cancer mortality. Although many efforts have been attempted, the prognosis is still not desirable in which surgical resection has remained as the last choice for the patients with advanced stage of disease [1]. It is worthy of mention that even surgery has not made a great step in mortality (improving 5-year survival rates from <4% if left untreated to 25–30% after resection) [2]. As seen in other cancers, pancreatic cancer also occurs due to genetic alterations and disturbances of gene expression [3]. One of regulatory-genetic factors that have been identified in the past decade is MicroRNAs (miRNAs). The miRNAs with 20–22 nucleotides (nt) in length are a group of small noncoding RNA molecules with considerate function in posttranscriptional phase [4]. Modulation of apoptosis and expression of genes involved in invasive behavior indicate the role of miRNAs in cancer. Depending on the cell, tissue, and disease type, the expression pattern of miRNAs could be different.

Today, it has been proved that deregulation in expression of miRNAs has important role in the pathogenesis of genetic and multifactorial cancers, as well as pancreatic cancer [5, 6]. Because the majority of human protein-coding genes could be regulated by miRNAs, equally it was assumed that miRNAs could have several target genes [7] though miRNAs are apt to downregulate target mRNAs [8]. These findings suggested that nearly more than one-third of human genes are regulated by miRNAs through various silencing pathways. Bearing in mind complex gene regulatory networks in biological systems, many scientific efforts have been devoted to draw “the big picture” in miRNA-mRNA interactions using the combination of experimental methods and computational approaches. Most often deregulation of miRNAs has reflected the pathophysiology of many cancers such as liver, prostate, and ovarian [9–11]. Moreover,
molecular disregulation of miRNAs is believed to play major roles in etiology of pancreatic cancer or be a consequence of tumor formation that could be used as a biomarker for tumor detection. Indeed expression of miRNAs correlated with outcome in pancreatic cancer patients [12–15]. Recognizing mRNAs regulated by miRNAs will help us for better understanding of biological roles of miRNAs [16]. Although the collected previous data seem to be a treasure trove, a large portion of data is false-positive or insignificant. Many computational methods have been developed to resolve this problem to extract precise results. In this way, researches on miRNAs-mRNAs interactions can lead us to pathways from their identification to their functional assignment in system biology. One motivation of systems biology research is to understand gene functions and up-to-date structural and functional annotations of genes [17, 18].

Pancreatic cancer is often diagnosed at a late stage and surgical resection, if possible, is too difficult. Recognizing early diagnosis biomarkers and molecular targets therapy need to discover that was one important aim in experimental studies [19, 20]. Furthermore, investigation of miRNAs-mRNAs interactions in this cancer would be new approach to gaining insight into complex biological processes not only for brighter understanding of pancreatic cancer etiology but also for designing new prognostic and diagnostic strategies. In this study, we performed a number of available software programs for the purpose of construct of most efficient miRNA-mRNA network analysis and visualization.

2. Methods

2.1. Search Studies and Datasets. PC-related miRNAs were collected from miR2Disease database (http://www.mir2disease.org/) database and also from the relevant literature. There were a total of 64 pancreatic cancer miRNAs, in which, 8 miRNAs were downregulated and 56 miRNAs upregulated (Table 1). Overall upregulated miRNAs which have been described as oncogenes were selected for miRNA-mRNA network analysis. The same strategy was performed for mRNA expression pattern in PC. Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo), ArrayExpress (http://www.ebi.ac.uk/arrayexpress/), Stanford Microarray Database (http://smd.princeton.edu/), and PubMed (http://www.ncbi.nlm.nih.gov/pubmed) are comprehensive databases for gene expression.

2.2. miRNA-mRNA Interaction Analysis. In this study, information of miRNAs and miRNAs expression profiles retrieved from different molecular methods; therefore we integrated the data of miRNA and gene expression as not matched samples by MAGIA tool (http://gencomp.bio.unipd.it/magia) because matched data (samples have been produced in a lab) were not available. Not matched data analysis option in MAGIA tool is functional for samples in public database. The data collection and processing give rise to two matrices, for miRNAs and genes. Each matrix includes two classes of samples (T for tumor and N for normal), for the mRNA and gene matrices. The meta-analysis separately considers each matrix to identify expression profiles significantly variable among classes and integrate results with target predictions. Note that expression matrices must be tab-delimited text files; the first row must contain sample names; the first column must contain gene/miRNA IDs.

2.3. Integrative Analysis with Not Matched Expression Matrices in Multistep Procedure

(1) We selected ID type (RefSeq) and “meta-analysis” from the list of available methods for the integrated analysis. MAGIA will calculate LIMMA \( P \) values of differential expression, which are then combined by using the inverse chi-square distribution to identify oppositely variable miRNA-gene pairs.

(2) Select a target prediction algorithm (miRanda, PITA, and TargetScan) or a combination thereof. In this study to ensure more, RefSeq ID and the intersection of all three algorithms were used.

(3) Upload miRNAs and genes expression matrices.

(4) Finally, construction of network was performed via the sequence complementarity between miRNA and mRNA. Functional enrichment analysis was directly uploaded, with corresponding settings on the DAVID page. Moreover for network visualization a text file was imported in Cytoscape software. The Evolutionary Trace Annotation (ETA) method in the Cytoscape network visualization environment was carried out for predicting the functional associations among miRNAs and mRNAs [31]. This software supports the visual features of nodes and edges, such as shape, color, and size. In this network length of edges are proportional to the log \( P \) value, therefore genes that are located on the farther representing by smaller amount of \( P \) value.

3. Gene Ontology and Pathway Analysis

The Sequence Retrieval System GeneDecks (http://www.genecards.org/gene_decks) that are a novel analysis tool for transcriptome analyses and comprise the largest databases of genes were used to establish the targeted gene lists. Furthermore, DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov/) were used for understanding the biological meaning behind large lists of genes, to obtain gene ontology and pathway information for significant downregulated target genes in pancreatic cancer. The important functions and biological roles of target genes and their association with pancreatic cancer were assessed by MALACARD server (http://www.malacards.org/).

4. Results

4.1. miRNAs and mRNA Expression Profiling. Overall 64 pancreatic cancer miRNAs, in which 8 miRNAs were downregulated and 56 miRNAs upregulated, have been identified from databases. The 8 downregulated miRNAs were not
Table 1: Designated studies for expression profile of microRNAs in pancreatic cancer.

| Number | References | Detection method       | microRNAs                                                                 |
|--------|------------|------------------------|---------------------------------------------------------------------------|
| 1      | [21]       | Northern blot, qRT-PCR | hsa-let-7f-1, hsa-let-7d, miR-21, miR-212, miR-16-1, miR-424, miR-92-1, miR-107, miR-181c, miR-15b, miR-155, miR-24-1, miR-24-2, miR-301, miR-376a, miR-181a, miR-221, miR-100, and miR-125-1 |
| 2      | [22]       | Microarray             | miR-205, miR-99a, miR-21, miR-210, miR-213, miR-107, miR-10a, miR-10b, miR-181b-1, miR-181b-2, miR-181c, miR-181d, miR-143, miR-199a-1, miR-199a-2, miR-155, miR-222, miR-223, miR-23a, miR-23b, miR-181a, miR-220, miR-221, miR-100-1, miR-100-2, miR-103-2, miR-125a, miR-125b-1, miR-146a, and miR-127 |
| 3      | [6]        | Microarray             | miR-20a, miR-21, miR-214, miR-92-2, miR-107, miR-128b, miR-181b-1, miR-199a-1, miR-223, miR-24-1, miR-24-2, miR-25, miR-29b-2, miR-30c, miR-32, miR-17-5p, miR-221, miR-106a, miR-146a, and miR-191 |
| 4      | [23]       | Northern blot, qRT-PCR | miR-21                                                                 |
| 5      | [5]        | Northern blot, qRT-PCR | miR-21, miR-107, and miR-103                                             |
| 6      | [24]       | Northern blot, qRT-PCR | miR-155                                                                 |
| 7      | [25]       | Northern blot, qRT-PCR | miR-107                                                                 |
| 8      | [26]       | Northern blot, qRT-PCR | miR-21                                                                 |
| 9      | [27]       | Northern blot, qRT-PCR | miR-155, miR-203, miR-210, and miR-222                                    |
| 10     | [28]       | Northern blot, qRT-PCR | miR-21 and miR-221                                                         |
| 11     | [29]       | Northern blot, qRT-PCR | miR-10a                                                                  |
| 12     | [30]       | qRT-PCR, luciferase assay | miR-214                                                                |

Table 1: Designated studies for expression profile of microRNAs in pancreatic cancer.

| Number | References | Detection method       | microRNAs                                                                 |
|--------|------------|------------------------|---------------------------------------------------------------------------|
| 1      | [21]       | Northern blot, qRT-PCR | hsa-let-7f-1, hsa-let-7d, miR-21, miR-212, miR-16-1, miR-424, miR-92-1, miR-107, miR-181c, miR-15b, miR-155, miR-24-1, miR-24-2, miR-301, miR-376a, miR-181a, miR-221, miR-100, and miR-125-1 |
| 2      | [22]       | Microarray             | miR-205, miR-99a, miR-21, miR-210, miR-213, miR-107, miR-10a, miR-10b, miR-181b-1, miR-181b-2, miR-181c, miR-181d, miR-143, miR-199a-1, miR-199a-2, miR-155, miR-222, miR-223, miR-23a, miR-23b, miR-181a, miR-220, miR-221, miR-100-1, miR-100-2, miR-103-2, miR-125a, miR-125b-1, miR-146a, and miR-127 |
| 3      | [6]        | Microarray             | miR-20a, miR-21, miR-214, miR-92-2, miR-107, miR-128b, miR-181b-1, miR-199a-1, miR-223, miR-24-1, miR-24-2, miR-25, miR-29b-2, miR-30c, miR-32, miR-17-5p, miR-221, miR-106a, miR-146a, and miR-191 |
| 4      | [23]       | Northern blot, qRT-PCR | miR-21                                                                 |
| 5      | [5]        | Northern blot, qRT-PCR | miR-21, miR-107, and miR-103                                             |
| 6      | [24]       | Northern blot, qRT-PCR | miR-155                                                                 |
| 7      | [25]       | Northern blot, qRT-PCR | miR-107                                                                 |
| 8      | [26]       | Northern blot, qRT-PCR | miR-21                                                                 |
| 9      | [27]       | Northern blot, qRT-PCR | miR-155, miR-203, miR-210, and miR-222                                    |
| 10     | [28]       | Northern blot, qRT-PCR | miR-21 and miR-221                                                         |
| 11     | [29]       | Northern blot, qRT-PCR | miR-10a                                                                  |
| 12     | [30]       | qRT-PCR, luciferase assay | miR-214                                                                |

4.2. miRNA-mRNA Network Analysis. Figure 1 shows the miRNA-mRNA interaction network and mRNA targets of differentially expressed miRNAs in pancreatic cancer that have been evaluated by gene networking tools (MAGIA and Cytoscape). This network consists of 217 nodes for mRNA, 15 nodes for miRNA, and 241 edges that show 241 regulations between 15 miRNAs and 217 genes. The miRNAs are presented in green circle while other circles offer for mRNAs that are existing in yellow, orange, brick red, and red based on the number of their regulating miRNAs. In this network, all edges of miRNAs (green circle) tend to mRNAs (circles by other colors), because miRNAs regulate mRNAs. If you zoom in Figure 1, you will find more details regarding network. Generally, when the colors tend to be red from yellow, the numbers of interactions increase. Yellow color represents one interaction while orange color represents two; brick red color, three; and red color, four interactions. On the other hand, P values of some of mRNA, which were assigned to their interaction with miRNAs, were more than 0.05. Therefore, they did not enter network. According to this network 197 target genes from 217 are regulate by four miRNAs.

4.3. Target Gene Analysis in Pancreatic Cancer. GeneCards is a searchable, combined, database of human genes that provides concise genomic related information, on all known and expected human genes. A portion of the GeneCards is related to the “Gene Associated with Disease” that represents proven roles of each gene in various diseases based on studies that have been done to date. GeneCards information displayed 20 of 217 expresional genes in interaction with fifteen miRNAs in the network which have had a permanent role in cancer of pancreas. We also have benefited Malacard site to understand how much every 20 genes are affective. Malacard score is sign of relationship of this gene to pancreas cancer that are presented in Table 2. Represented score in this site equals the rank of GenDecks P value and gene-associated score, multiple by the product of the logs of the ranks in gene cards search hit scores for each of genes. In addition to these 20 genes, the roles of 54 genes in this network are approved in other cancers especially gastrointestinal cancer. Therefore, 74 genes of 217 genes in the network are approved genes regarding cancer.

Moreover, mRNAs that are targeted with more than one miRNA are listed in Table 3. This list describes some of the most notable genes and interactions between miRNAs and target genes in pancreatic cancer. According to these
network.

findings, our network revealed that ACVR2B, GFRA1, and MTHFR are the most gene transcripts that are regulated by miRNAs and their relationships to pancreatic cancer were confirmed previously. The importance of mentioned three target genes rather than others is that they are shared in Tables 2 and 3. These findings revealed that genes which are known specifically for cancer of pancreas (Table 2) are regulated by more than one miRNA under pancreas cancer condition (Table 3). In other words, there is a specific control on expression of these three genes in deployment of pancreatic cancer.

There are other genes in this network that are controlled and regulated by more than one miRNA (Table 3). However, their role has not been studies clearly in pancreatic cancer. In addition, miR-24, miR-210, miR-221, and miR-222 are the most important among miRNAs. According to Figure 1, many of existing mRNAs in the networks are controlled and regulated by these four miRNAs. The important one is miR-24. Because many of target genes represented in Tables 2 and 3 are controlled and regulated by this type of miRNA.

**Figure 1:** Interaction network of mRNAs and upregulated miRNAs in pancreatic cancer based on Cytoscape 3 software. Green circles show miRNAs and other circles offer for mRNAs that are existing in yellow, orange, brick red, and red based on the number of their regulating miRNAs. When the colors tend to be red from yellow, the numbers of interactions increase. Yellow color represents one interaction. It means mRNA is controlled and regulated by miRNA. Orange color represents two interactions; brick red color, three interactions; and red color, four interactions and regulate by four miRNAs. Length edges are log P value. (If you zoom in the figure, you will find more details regarding network.)
In our study, we used system biology tools and high-throughput experiment data (expression profiles mRNA/miRNA from literatures) to analyze the interaction of miRNAs with mRNAs that are targeted by them and are involved in cancer of pancreas. In complex diseases like cancer the function of genes deregulate in overlapping pathways. Tumor cells use preexisting pathways in altered ways and they combine components of these pathways in an innovative way. The relevance of miRNAs in pancreatic cancer and its therapy is now under intense investigation [12, 32]. Individual miRNAs can target multiple mRNAs genes that are involved in self-organization and homeostasis of living organisms. Analyzing the network of gene-expression data make known the organizational of gene expression and recognize new potential drug targets in cancer.

This study has determined that 197 of 217 genes are targeted and downregulated by only four of the miRNAs: miR-24, miR-210, miR-221, and miR-222 in which miR-24 was the most important because numerous target genes, represented in Tables 2 and 3, are controlled and regulated by miR-24. This miRNA suppresses the expression of tumor suppressor genes and cell cycle control genes by targeting the 3’-UTR of their mRNA [33]. Moreover miR-210, miR-221, and miR-222 were significantly proficient to regulate more than one target gene which were associated with pancreatic cancer in this network. Remarkably, many of miRNAs which in previous studies were significantly and specifically determined had no target in this network. Indeed, large amount of related genes to pancreatic cancer in published studies not to be found in this network revealed they are not regulated by any of 56 types of candidate miRNAs. MTHFR, GFRA1, and ACVR2B were recognized as the most important controlled genes in present network. We showed that ACVR2B (Activin A receptor, type IIB) gene linked to four types of miRNA and regulated many physiologic and pathobiology processes including immunosuppression, carcinogenesis, insulin secretion, and pancreas development [34]. The expression pattern and mutations of ACVR2B has been approved in previous studies [34, 35]. Moreover, GFRA1 (GDNF family receptor alpha-1) is a potent neurotrophic factor that plays a key role in the control of neuron survival and differentiation. Somewhere, this gene is introduced as a function of age [36]. Also, MTHFR (methylenetetrahydrofolate reductase) was proposed to participate in metabolic pathway. One carbon pool is provided by foliate implicated in blood circulation, cellular amino acid metabolic process, methionine biosynthetic process, and oxidation reduction [37]. Association of these target genes with the pathophysiology of pancreatic cancer has been already validated [32, 38]. Indeed their functional roles are explained by biological process, molecular function, and cellular component GO annotations. In eukaryotic cells, GO annotations of related proteins to target genes revealed several processes through their domains that carry out diverse molecular functions and participate in multiple alternative interactions with other proteins, organelles, or locations in the cell (Table 4).

### 6. Discussion

### 5. Gene Ontology Annotation

GO annotation strategies also permit the functional annotation of candidate genes that were uniquely downregulated in pancreatic cancer. In Table 4, gene ontology (GO) annotations for predicted target mRNAs in miRNA-mRNA interaction network were determined by DAVID and GeneDecks. In view of phenotype, the miRNA target genes of the current network are organized in three groups mortality/aging (50 genes), growth/size (42 genes), and behavior/neurological (36 genes). Genes were predominantly grouped into functional classes of protein binding (63 genes), sequence-specific DNA binding transcription factor activity (19 genes), and zinc ion binding (20 genes) (Table 4). The most important biological processes are transcription, DNA-dependent, and smoothened signaling pathway. Cellular constituents of genes mainly belong to the cytoplasm, nucleolus, and nucleus. This term denote the place of activity of a gene product. The evolutionary domains of miRNAs target genes products in the presented network are Ser/Thr-kinase-AS, PHF, Prot-kinase-cat-dom, Znf-PHD-finger, Kinase-like-dom, and Znf-PHD.

### Table 2: Genes in association with pancreatic cancer are shown in the network.

| Number | Target gene | Malacard score | microRNA   | P value |
|--------|-------------|----------------|------------|---------|
| 1      | ARL4C       | 16.286         | miR-181b   | 0.01238 |
| 2      | CCR9        | 12.916         | miR-24     | 0.00077 |
| 3      | ACVR2B      | 12.855         | miR-181b   | 0.01174 |
| 4      | SMAD2       | 12.814         | miR-24     | 0.01831 |
| 5      | ABCC5       | 12.855         | miR-103    | 0.02103 |
| 6      | GFRA1       | 12.056         | miR-210    | 0.02811 |
| 7      | CASP2       | 11.982         | miR-24     | 0.02287 |
| 8      | PTPN11      | 10.469         | miR-24     | 0.0054  |
| 9      | PPARA       | 10.283         | miR-222    | 0.04031 |
| 10     | CD34        | 10.128         | miR-24     | 0.00764 |
| 11     | PGR         | 9.519          | miR-24     | 0.02159 |
| 12     | LLGL1       | 8.843          | miR-24     | 0.01736 |
| 13     | MTHFR       | 8.68           | miR-103    | 0.04494 |
| 14     | SLC36A1     | 8.592          | miR-24     | 0.01746 |
| 15     | SPNS2       | 8.015          | miR-24     | 0.02632 |
| 16     | TGFB2       | 7.987          | miR-181d   | 0.03812 |
| 17     | POXL        | 7.57           | miR-221    | 0.01018 |
| 18     | HIPK2       | 7.531          | miR-24     | 0.02163 |
| 19     | GNE         | 7.457          | miR-24     | 0.01318 |
| 20     | TCF3        | 7.151          | miR-24     | 0.01106 |
Table 3: Genes target that are regulated with more than one microRNA and are displayed in the network.

| Number | Target gene | Description | GO annotation | microRNAs                                    | \( P \) value |
|--------|-------------|-------------|---------------|-----------------------------------------------|---------------|
| 1      | ACVR2B*     | Active in A receptor, type IIB | Muscle growth | hsa-miR-181b, hsa-miR-103, hsa-miR-210, hsa-miR-107 | 0.017448      |
| 2      | AP3S2       | Adaptor-related protein complex 3, sigma 2 subunit | Protein transporter activity | hsa-miR-24, hsa-miR-210 | 0.004154      |
| 3      | C22orf29    | Chromosome 22 open reading frame 29 | Protein binding; play a key role in apoptotic signaling activity | hsa-miR-103, hsa-miR-107 | 0.001947      |
| 4      | C22orf46    | Chromosome 22 open reading frame 46 | Transcription regulation | hsa-miR-221, hsa-miR-181d, hsa-miR-181b | 0.000716      |
| 5      | DYRK2       | Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 | Translation insulin regulation of translation and DNA damage | hsa-miR-103, hsa-miR-210 | 0.024406      |
| 6      | GFRA1*      | GDNF family receptor alpha 1; development of EGFR signaling pathway and axon guidance | Integrin binding and receptor binding | hsa-miR-221, hsa-miR-210 | 0.011847      |
| 7      | GPR107      | G protein-coupled receptor 107 | | hsa-miR-222, hsa-miR-210 | 0.012316      |
| 8      | HOOK3       | Hook microtubule-tethering protein 3 | Attach to microtubule, and more divergent C-terminal domains, which mediate binding to organelles | hsa-miR-222, hsa-miR-221, hsa-miR-181b | 0.000872      |
| 9      | IRGQ        | Immunity-related GTPase family, Q | | hsa-miR-24, hsa-miR-222 | 0.01954       |
| 10     | KSR2        | Kinase suppressor of ras 2 | Protein serine/threonine kinase activity and MAP-kinase scaffold activity | hsa-miR-24, hsa-miR-222 | 0.030827      |
| 11     | MTHFR*      | Methylenetetrahydrofolate reductase (NAD(P)H) activity and modified amino acid binding | Methylenetetrahydrofolate reductase (NADPH) activity and modified amino acid binding | hsa-miR-103, hsa-miR-107 | 0.044941      |
| 12     | N4BP1       | NEDD4 binding protein 1 | Protein binding | hsa-miR-222, hsa-miR-221 | 0.001158      |
| 13     | NXF1        | Nuclear RNA export factor 1 | Nucleocytoplasmic transporter activity and nucleotide binding mRNA processing and transport of mature mRNAs derived from intronless transcripts | hsa-miR-24, hsa-miR-31 | 0.005296      |
| 14     | PGPEP1      | Pyroglutamyl-peptidase I | Cysteine-type peptidase activity | hsa-miR-31, hsa-miR-210 | 0.000891      |
| 15     | PLEKHM3     | Pleckstrin homology domain containing, family M, and member 3 | Phospholipid binding and metal ion binding | hsa-miR-222, hsa-miR-221, hsa-miR-146a | 0.005244      |
| 16     | TSPAN14     | Tetraspanin 14 | | hsa-miR-24, hsa-miR-210 | 0.000255      |
| 17     | UBN2        | Ubinuclein 2 | | hsa-miR-24, hsa-miR-222 | 0.001363      |
| 18     | ZBTB42      | Zinc finger and BTB domain containing 42 | DNA binding and zinc ion binding transcriptional repressor | hsa-miR-181d, hsa-miR-181b | 0.025341      |

*Target gene that are common on Tables 2 and 3.

We confess that many of obtained outputs of high-throughput experiments do not exist in this network anymore. The reason of such different gene expression profiles from experimental studies of pancreatic cancer is that there was no study simultaneous to analysis of miRNAs and mRNAs in the same condition. Moreover, considering cognitive world of transcriptomic and regulating factors, it is not expected that miRNAs act just as regulator of mRNAs, because new findings show that target of some miRNAs is long noncoding RNA (lncRNAs). In addition, expressions of many RNAs are controlled by other regulating factors instead of miRNAs. However, according to this matter that
more than 60% of expressions of protein producer genes in human are regulated by miRNAs and this fact that the more important and famous regulating mechanism for expression genes are miRNAs, one of scientists’ purposes is studying and controlling them under different circumstances.

7. Conclusion

Previous works investigated just expression of miRNAs or mRNAs related to pancreatic cancer that are a rich treasury of information. They are possible to achieve to biomarkers. However, by drawing connecting networks, it leads us to the main passkeys in regard to the relationship between miRNAs and mRNAs in occurrence or development of cancer under certain conditions. We demonstrate bioinformatics approach to study the key communication between mRNAs and miRNAs. The obtained results of this network revealed that 217 mRNA were significantly regulated by 15 miRNAs in pancreatic cancer. The miR-24 has been reported as most important miRNA and genes such as ACVR2B, GFRA1, and MTHFR are most involved in pancreatic cancer. Therefore this study provides new opportunities for studying novel molecular pathways of pancreatic cancer pathogenesis and for developing new therapeutic approaches.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

This Study was supported by grants from the Digestive Disease Research Center, Tehran University of Medical Sciences.

References

[1] J. E. Niederhuber, M. F. Brennan, and H. R. Menck, “The national cancer data base report on pancreatic cancer,” Cancer, vol. 76, no. 9, pp. 1671–1677, 1995.
[2] Y. Shaib, J. Davila, C. Naumann, and H. El-Serag, “The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. population-based study,” American Journal of Gastroenterology, vol. 102, no. 7, pp. 1377–1382, 2007.
[3] M. Hidalgo, “Pancreatic cancer,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1605–1617, 2010.
[4] C. Sevignani, G. A. Calin, L. D. Siracusa, and C. M. Croce, “Mammalian microRNAs: a small world for fine-tuning gene expression,” Mammalian Genome, vol. 17, no. 3, pp. 189–202, 2006.
[5] C. Roldo, E. Missiaglia, J. P. Hagan et al., “MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4677–4684, 2006.
[6] S. Volinia, G. A. Calin, C. G. Liu et al., “A microRNA expression signature of human solid tumors defines cancer gene targets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2257–2261, 2006.
[7] Y. Watanabe and A. Kanai, “Systems biology reveals microRNA-mediated gene regulation,” Frontiers in Genetics, vol. 2, p. 29, 2011.
[8] L. P. Lim, N. C. Lau, P. Garrett-Engele et al., “Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs,” Nature, vol. 433, no. 7027, pp. 769–773, 2005.
[9] R. Grützmann, H. Boriss, O. Ammerpohl et al., “Meta-analysis of microarray data on pancreatic cancer defines a set of
commonly dysregulated genes,” Oncogene, vol. 24, no. 32, pp. 5079–5088, 2005.

[10] Q. Zou, J. Li, C. Wang et al., “Approaches for recognizing disease genes based on network,” BioMed Research International, vol. 2014, Article ID 416323, 10 pages, 2014.

[11] L. Guo, Y. Zhao, S. Yang et al., “Integrative analysis of miRNA-miRNA and miRNA-miRNA interactions,” BioMed Research International, vol. 2014, Article ID 907420, 8 pages, 2014.

[12] C. He, H. Jiang, S. Geng et al., “Analysis of whole genomic expression profiles and screening of the key signaling pathways associated with pancreatic cancer,” International Journal of Clinical and Experimental Pathology, vol. 5, no. 6, pp. 537–546, 2012.

[13] Y.-P. Zhao, G. Chen, B. Feng, T.-P. Zhang, E.-L. Ma, and Y.-D. Wu, “Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer,” Chinese Medical Journal, vol. 120, no. 20, pp. 1743–1752, 2007.

[14] H. Han, D. J. Bearss, L. Browne, R. Calaluce, R. B. Nagle, and D. D. von Hoff, “Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray,” Cancer Research, vol. 62, no. 10, pp. 2890–2896, 2002.

[15] C. D. Logsdon, D. M. Simeone, C. Binkley et al., “Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer,” Cancer Research, vol. 63, no. 10, pp. 2649–2657, 2003.

[16] N. H. Tan Gana, A. F. B. Victoriano, and T. Okamoto, “Evaluation of online miRNA resources for biomedical applications,” Genes to Cells, vol. 17, no. 1, pp. 11–27, 2012.

[17] Q. Cui, Z. Yu, E. O. Purisima, and E. Wang, “Principles of microRNA regulation of a human cellular signaling network,” Molecular Systems Biology, vol. 2, p. 46, 2006.

[18] Y. Cai, T. Huang, L. Chen et al., “Application of systems biology and bioinformatics methods in biochemistry and biomedicine,” BioMed Research International, vol. 2013, Article ID 651968, 2 pages, 2013.

[19] S. Bandypadhyay, R. Mitra, U. Maulik, and M. Q. Zhang, “Development of the human cancer microRNA network,” Silence, vol. 1, no. 1, article 6, 2010.

[20] P. Sood, A. Krek, M. Zavolan, G. Macino, and N. Rajewsky, “Cell-type-specific signatures of microRNAs on target mRNA expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 8, pp. 2746–2751, 2006.

[21] J. L. Eun, Y. Gusev, J. Jianget al., “Expression profiling identifies microRNA signature in pancreatic cancer,” International Journal of Cancer, vol. 120, no. 5, pp. 1046–1054, 2007.

[22] M. Bloomston, W. L. Frankel, F. Petrocca et al., “MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis,” Journal of the American Medical Association, vol. 297, no. 17, pp. 1901–1908, 2007.

[23] M. Dillhoff, J. Liu, W. Frankel, C. Croce, and M. Bloomston, “MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival,” Journal of Gastrointestinal Surgery, vol. 12, no. 12, pp. 2171–2176, 2008.

[24] M. Gironella, M. Seux, M.-J. Xie et al., “Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 41, pp. 16170–16175, 2007.

[25] K.-H. Lee, C. Lotterman, C. Karikari et al., “Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer,” Pancreatology, vol. 9, no. 3, pp. 293–301, 2009.

[26] T. Moriyama, K. Ohuchida, K. Mizumoto et al., “MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance,” Molecular Cancer Therapeutics, vol. 8, no. 5, pp. 1067–1074, 2009.

[27] T. Greither, L. F. Grochola, A. Udelnow, C. Lautenschlager, P. Würl, and H. Taubert, “Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival,” International Journal of Cancer, vol. 126, no. 1, pp. 73–80, 2010.

[28] J.-K. Park, E. J. Lee, C. Esau, and T. D. Schmittgen, “Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma,” Pancreas, vol. 38, no. 7, pp. e190–e199, 2009.

[29] F. U. Weiss, I. J. Marques, J. M. Woltering et al., “Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer,” Gastroenterology, vol. 137, no. 6, pp. 2136.e7–2145.e7, 2009.

[30] X. J. Zhang, H. Ye, C. W. Zeng, B. He, H. Zhang, and Y. Q. Chen, “Dysregulation of miR-15a and miR-214 in human pancreatic cancer,” Journal of Hematology and Oncology, vol. 3, article 46, 2010.

[31] M. E. Smoot, K. Ono, J. Ruscheinski, P.-L. Wang, and T. Ideker, “Cytoscape 2.8: new features for data integration and network visualization,” Bioinformatics, vol. 27, no. 3, pp. 431–432, 2011.

[32] O. Cavel, O. Shomron, A. Shabtay et al., “Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor,” Cancer Research, vol. 72, no. 22, pp. 5733–5743, 2012.

[33] A. Lal, F. Navarro, C. A. Maher et al., “miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3’ UTR microRNA recognition elements,” Molecular Cell, vol. 35, no. 5, pp. 610–625, 2009.

[34] K. Hildén, T. Tuuri, M. Erämaa, and O. Ritvos, “Expression of type II activin receptor genes during differentiation of human K562 cells and cDNA cloning of the human type IIB activin receptor,” Blood, vol. 83, no. 8, pp. 2163–2170, 1994.

[35] L. T. Roten, M. P. Johnson, S. Forsmo et al., “Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study),” European Journal of Human Genetics, vol. 17, no. 2, pp. 250–257, 2009.

[36] H. Funahashi, Y. Okada, H. Sawai et al., “The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells,” Journal of Surgical Oncology, vol. 91, no. 1, pp. 77–83, 2005.

[37] M. Födinger, W. H. Hörl, and G. Sunder-Plassmann, “Molecular biology of 5,10-methylenetetrahydrofolate reductase,” Journal of Nephrology, vol. 13, no. 1, pp. 20–33, 2000.

[38] S. Singh, G. Choudhuri, R. Kumar et al., “Association of 5,10-methylenetetrahydrofolate reductase C677T polymorphism in susceptibility to tropical chronic pancreatitis in north Indian population,” Cellular and Molecular Biology, vol. 58, no. 1, pp. 122–127, 2012.